Version Superseded: 18/03/2022
Point in time view as at 15/02/2021. This version of this provision has been superseded.
You are viewing this legislation item as it stood at a particular point in time. A later version of this or provision, including subsequent changes and effects, supersedes this version.
Note the term provision is used to describe a definable element in a piece of legislation that has legislative effect – such as a Part, Chapter or section.
There are currently no known outstanding effects for the The Health Protection (Coronavirus, International Travel) (Wales) (Amendment) (No. 3) Regulations 2021, Section 4.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
4. After Schedule 1A (testing before arrival in Wales) to the International Travel Regulations insert—
Regulation 6B
1. Personal details—
(a)full name;
(b)sex;
(c)ethnicity;
(d)date of birth;
(e)passport number, or travel document reference number (as appropriate);
(f)NHS number (if known and applicable);
(g)telephone number;
(h)home address;
(i)email address.
2. Journey details—
(a)the address of the suitable premises at which P intends to reside as required by regulation 7 or 8;
(b)the date of arrival in the United Kingdom;
(c)coach number;
(d)flight number of vessel name;
(e)the date on which P was last in a non-exempt country or territory;
(f)the country or territory P will be travelling from when P arrives in the United Kingdom, and any country or territory P will have been in as part of that journey.
Regulation 6B
1. A day 2 test complies with this paragraph where—
(a)it is a semi-quantitative test for the detection of coronavirus which—
(i)targets a minimum of two distinguishable SARS-CoV-2 genes other than the S gene and performance reference controls,
(ii)includes routine in silico assurance against every variant of concern, and
(iii)produces a test solution that provides extracted nucleic acid that is suitable for whole genome sequencing using a specified method,
(b)the manufacturer of any device used for the purposes of the test states that the device—
(i)uses an established molecular detection method,
(ii)has a specificity and a sensitivity greater than 99% (with a 95% two-sided confidence interval entirely above 97%),
(iii)has a limit of detection of less than or equal to 1000 SARS-CoV-2 copies per millilitre, and
(iv)is suitable for identifying every variant of concern, and
(c)any device used for the purposes of the test—
(i)can be put into service in accordance with Part 4 of the Medical Devices Regulations 2002(1), other than solely by virtue of regulation 39(2) of those Regulations, and
(ii)has been validated no more than 18 months before the test is administered or provided to P.
2. A day 8 test complies with this paragraph where—
(a)it is a semi-quantitative test for the detection of coronavirus which targets a minimum of two distinguishable SARS-CoV-2 genes other than the S gene and performance reference controls,
(b)the manufacturer of any device used for the purposes of the test states that the device—
(i)uses an extracted molecular method,
(ii)has a specificity and a sensitivity greater than 95% (with a 95% two-sided confidence interval entirely above 90%), and
(iii)has a limit of detection of less than or equal to 1000 SARS-CoV-2 copies per millilitre, and
(c)any device used for the purposes of the test—
(i)can be put into service in accordance with Part 4 of the Medical Devices Regulations 2002, other than solely by virtue of regulation 39(2) of those Regulations, and
(ii)has been validated no more than 18 months before the test is administered or provided to P.
3. In this Schedule—
(a)“specified method” means a targeted sequence method specific to SARS-CoV-2 or an equivalent—
(i)amplicon method, or
(ii)sequence bait capture method;
(b)“validated”, in relation to a device, means confirmed as having a sensitivity of at least 97% and a specificity of at least 99% for at least 150 positive samples and 250 negative samples, by—
(i)the Welsh Ministers,
(ii)the National Institute for Health and Care Excellence, or
(iii)a laboratory which is accredited by the United Kingdom Accreditation Service (“UKAS”) to ISO standard 15189 or ISO/IEC standard 17025, other than a laboratory which processes tests provided by the test provider for the purposes of this Schedule or is owned by the test provider;
(c)“variant of concern” means a variant of SARS-CoV-2 identified in a designation made by the relevant expert UK Group (currently NERVTAG) for the purposes of these Regulations and published in a way that the Welsh Ministers consider to be appropriate.”
Commencement Information
I1Reg. 4 in force at 15.2.2021 at 4.00 a.m.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area. The revised version is currently only available in English.
Original (As Enacted or Made) - English: The original English language version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Original (As Enacted or Made) - Welsh:The original Welsh language version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search. A point in time version is only available in English.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: